External validation of the IMPROVE bleeding Risk Assessment Model in medical patients

Thrombosis and Haemostasis

Volumn 116, Issue 3, 2016, Pages 530-536

  Rosenberg, David J ^a   Press, Anne ^a   Fishbein, Joanna ^b   Lesser, Martin ^b   McCullagh, Lauren ^a   McGinn, Thomas ^a   Spyropoulos, Alex C ^a,b  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Anticoagulants; Bleeding risk; Medical patients; Risk Assessment Model; Validation

Indexed keywords

ADULT; AGED; ARTICLE; BLEEDING; DIAGNOSTIC ACCURACY; ELECTRONIC HEALTH RECORD; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HOSPITAL ADMISSION; HUMAN; MALE; MENORRHAGIA; PEPTIC ULCER; PRIORITY JOURNAL; RHEUMATIC DISEASE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; FIBRINOLYTIC THERAPY; HOSPITALIZATION; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; VALIDATION STUDY; VENOUS THROMBOEMBOLISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOLYTIC THERAPY; VENOUS THROMBOEMBOLISM;

EID: 84989211289     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-01-0003     Document Type: Article

References (17)

1. Tapson VF, Hyers TM, Waldo AL, et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med 2005; 165: 1458–1464.
2. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756–764.
3. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793–800.
4. Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 3719610: 387–394.
5. Douketis JD. Prevention of venous thromboembolism in hospitalised medical patients: addressing some practical questions. Curr Opin Pulm Med 2008; 145: 381–388.
6. Qaseem A, Chou R, Humphrey LL, et al. Venous thromboembolism prophylaxis in hospitalised patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011; 155: 625–632.
7. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence〿Based Clinical Practice Guidelines. Chest 2012; 141: e195S-e226S.
8. Spyropoulos AC, Anderson FA, Fitzgerald G, et al. Predictive and associative models to identify hospitalised medical patients at risk for VTE. Chest 2011; 140: 706–714.
9. Rosenberg D, Eichorn A, Alarcon M, et al. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc 2014; 3: e001152.
10. Huang W, Anderson FA, Spencer FA, et alJ. Risk-assessment models for predicting venous thromboembolism among hospitalised non-surgical patients: a systematic review. J Thromb Thrombolysis 2013; 35: 67–80.
11. Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011; 139: 69–79.
12. Arnason T, Wells PS, Van Walraven C, et al. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 2006; 118: 253–262.
13. Meijer K, Schulman S. The absence of ’minor’ risk factors for recurrent venous thromboembolism: a systematic review of negative predictive values and negative likelihood ratios. J Thromb Haemost 2009; 7: 1619–1628.
14. Hostler DC, Marx ES, Moores LK, et al. Validation of the IMPROVE Bleeding Risk Score. Chest 2015; Epub ahead of print.
15. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793–800.
16. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874–879.
17. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 2006; 332: 325–329.